58 results about "Calcium-binding protein" patented technology

Provided are an marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a calcium-binding protein S100A7, S100A8, or S100A10.

The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, adhesion/extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding/repair/replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G/regulator proteins, inhibitor proteins, motor/contractile proteins, phosphatase, protease, Ser/Thr protein kinases, Protein kinase (Tyr)s, receptor/channel/cell surface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function.

The invention provides application of SMOC2 gene (SPARC related modular calcium binding2, with the Chinese name of secreting modular calcium binding protein 2; smooth muscle related protein 2) in preparation of medicine for detecting or treating endometrial cancer and ovarian cancer. A tissue chip comprising 157 endometrial cancer tissue specimens, 30 normal proliferative phase endometrium tissue specimens and 30 normal secretory phase endometrium tissue specimens is established by utilizing a tissue microarray technology, the expression conditions of SMOC2 in the specimens are detected by utilizing the immunohistochemical technique, the positive expression rate of the SMOC2 in the normal tissue of the endometrium is far lower than the positive expression rate in the endometrial cancer, and the expression intensity is positively correlated to muscular invasion depth of the endometrial cancer and tumor grading of the endometrial cancer. Therefore, the SMOC2 gene can be used for preparing the medicine for detecting or treating endometrial cancer. The medicine is reliable in experimental result and high in repeatability and has good clinical application prospect and good application values and social benefits.

The invention discloses nearly 480 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, acetyltransferases, actin binding proteins, adhesion proteins, apoptosis proteins, calcium-binding proteins, cell cycle regulation proteins, cell surface proteins, channel proteins, chaperone proteins, contractile proteins, cytokine proteins, cytoskeletal proteins, G protein regulators and GTPase activating proteins, guanine nucleotide exchange factors, helicase proteins, immunoglobulin superfamily proteins, inhibitor proteins, protein kinases, lipid kinases, ligases, lipid binding proteins, methytransferases, motor proteins, oxidoreductases, phosphotases, phosphodiesterases, phospholipases, proteases, receptor proteins, trascription factors, transferases, translation/transporter proteins, and ubiquitin conjugating system proteins.

The invention relates to a urine protein marker of breast cancer and applications thereof in diagnosis and prognosis. Specifically, the invention relates to applications of the urine protein marker of breast cancer in early diagnosis and disease monitoring of human breast cancer. The urine protein marker comprises beta-2 microglobulin, alpha-1-acid glycoprotein 1, programmed cell death 6 interacting protein, haptoglobin related protein, addiment C4-A, apolipoprotein A-IV, calcium binding protein, HLA-I histocompatibility antigen, A-3 alpha chain, pancreatic stone protein 1 alpha, blood coagulation factor XII, collectin 12, galectin-3 binding protein, vitamin D binding protein, and the like.

The invention discloses a preparation method of a Schistosoma japonicum calcium-binding EF-hand domain containing protein (SjEFCAB) recombinant antigen protein. The preparation method comprises the following steps of: designing SEQ ID NO.3 or a complementary chain 5' thereof as a primer and SEQ ID NO.4 or a complementary chain 3' thereof as a primer, and carrying out amplification on a Schistosoma japonicum SjEFCAB gene sequence; establishing and identifying Schistosoma japonicum SjEFCAB recombinant plasmids; and carrying out induction expression, purification and the like on recombinant protein. Besides, the invention further discloses an application of the Schistosoma japonicum SjEFCAB recombinant antigen protein prepared by using the method in preparation of products for detecting a serum antibody of a Schistosoma japonicum patient. Enzyme linked immunosorbent assay (ELISA) proves that the Schistosoma japonicum SjEFCAB recombinant antigen protein has higher sensitivity and specificity when used for diagnosing the Schistosoma japonicum, is a potential candidate target of diagnosis, and can be used as a target antigen for diagnosing the Schistosoma japonicum.

The invention relates to the technical field of biology, in particular to a plasma protein marker, a detection reagent or a detection tool for diagnosing severe-to-critical symptomsof the new coronalpneumonia. ELISA detection finds that concentrations of cholesterol ester transfer protein, calcium binding protein S100A8, calcium binding protein S100A9 and C reactive protein have significant differences in plasma of a severe patient and a critical patient, so that the accuracy of the OBC combination for predicting severe cases to critical cases is further determined.

The present application relates to improved recombinant protein production processes through the use of novel fusion tags. In particular, the present application discloses novel fused proteins comprising an aminoacidic sequence that corresponds to a fragment H or an aminoacidic sequence that corresponds to a calcium-binding protein excreted/secreted by the adult worm of Fasciola hepatisa, namely, Fh8 and Fh22 proteins, followed by an aminoacidic sequence that corresponds to a non-related protein fragment or protein, and methods for its preparation and its use thereof.

The present invention discloses a novel polypeptide, a human binding protein 42, the polynucleotide encoding the polypeptide and the method for producing the polypeptide by DNA recombinant technology. The invention also discloses the uses of the polypeptide in methods for treating various diseases, such as malignant tumour, hemopathy. HIV infection, immunological disease, and various inflammation, etc. The invention also discloses the agonists against the polypeptide and the therapeutic action thereof. The invention also discloses the uses of the polynucleotide encoding the novel human calcium binding protein 42.

The present invention provides a photoreactive reagent that binds specifically to Ca²⁺-binding proteins, links to them covalently after photo-activation, and labels them. The novel reagent enables the characterization, purification, inhibition and screening of Ca²⁺-binding proteins, as well as the preparation of a new affinity chromatography matrix and a new protein biosensor. The invention also relates to the use of the reagent in inhibiting apoptosis and necrosis and in diagnosing a disorder associated with a defect in the function of a Ca²⁺-binding protein, and in the preparation of a medicament for treating such disorders.

Methods useful in the regulation of myocardial contraction are disclosed. The methods are useful in the regulation of heart function. The invention reveals that sorcin overexpression enhances cardiac contractile performance and establishes the concept of sorcin as a regulator of myocardial contractility. The invention also provides screening assays that allow for the identification of agents that modulate sorcin expression. Such agents are useful, for example, for diagnosing cardiac contractile function associated disorders in subjects, and treating the subjects with the agents identified as being able to modulate sorcin expression.

The invention discloses and provides a recombinant histolytic clostridium type II collagenase. The recombinant histolytic clostridium type II collagenase comprises a histolytic clostridium type II collagenase and a tag protein connected to an N end of the histolytic clostridium type II collagenase, the tag protein comprises fasciola hepatica calcium binding protein (Fh8); preferably, the amino acid sequence of the fasciola hepatica calcium binding protein is SEQ ID NO: 2. The invention also provides an expression vector and recombinant engineering bacteria for expressing the recombinant clostridium histolyticum type II collagenase, and also provides a preparation method of the clostridium histolyticum type II collagenase. The recombinant clostridium histolyticum type II collagenase can be efficiently expressed, does not form inclusion bodies, is easy to separate and purify, and is beneficial to industrial production of the clostridium histolyticum type II collagenase.

The present invention provides a human apoptosis-related calcium-binding protein (HARC) and polynucleotides which identify and encode HARC. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HARC and a method for producing HARC. The invention also provides for agonists, antibodies, or antagonists specifically binding HARC, and their use, in the prevention and treatment of diseases associated with expression of HARC. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HARC for the treatment of diseases associated with the expression of HARC. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HARC.

The invention discloses a method and a system for improving the repair capability of mesenchymal stem cells. The method comprises the following steps: obtaining mesenchymal stem cells with stable subculture; culturing the mesenchymal stem cells for 24-48 hours under the conditions of ischemia and hypoxia; transfecting the mesenchymal stem cells subjected to hypoxia and ischemia culture by using calcium binding protein; and culturing the transfected mesenchymal stem cells under a normal oxygen condition for a preset time for later use. The system comprises a mesenchymal stem cell obtaining module, an ischemia and hypoxia culture module, a transfection module and a normal oxygen culture module. According to the invention, through hypoxia-ischemia culture and calcium binding protein transfection, the repair capability of the mesenchymal stem cells after transplantation is improved.